In the future, in patients with hypoacetylated colon cancer, the efficacy of reversing K153 acetylation level, probably by inhibiting SIRT2, can be tested as an adjuvant therapy for CRC. The gene discussed is SIRT2; the disease is colorectal carcinoma.